SCHEMBL3490440

SCHEMBL3490440

COC(=O)c1ccc2ncn(-c3ccccc3Cl)c2c1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.56
MAPT P10636 1/20 0.52
RAB9A P51151 1/20 0.52
HCAR1 Q9BXC0 1/20 0.45
SRC P12931 1/20 0.45
LCK P06239 1/20 0.45
HTT P42858 2/20 0.44
ALOX15 P16050 1/20 0.44
HPGD P15428 5/20 0.44
LMNA P02545 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.42
ADRA2B P18089 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
F9 P00740 1/20 0.41
ACSS2 Q9NR19 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3492954 0.83 FGFR1 (0.49) FGFR1RAB9AHCAR1HTTHPGD
SCHEMBL7975748 0.82 FGFR1 (0.81) FGFR1MAPTRAB9ASRCHTT
SCHEMBL3491384 0.82 ALDH1A1 (0.50) FGFR1MAPTRAB9AHTTHPGD
Hydrochloric Acid SCHEMBL7986510 0.81 FGFR1 (0.79) FGFR1MAPTRAB9ASRCHTT
SCHEMBL2831063 0.79 MAPT (0.62) FGFR1MAPTRAB9ASRCHTT
SCHEMBL17825717 0.77 FGFR1 (0.55) FGFR1MAPTRAB9ASRCHPGD
SCHEMBL14500118 0.76 HCAR1 (0.50) FGFR1HCAR1LCKHTTHPGD
SCHEMBL14852093 0.76 FGFR1 (0.66) FGFR1MAPTRAB9ASRCHTT
SCHEMBL2345129 0.76 FGFR1 (0.70) FGFR1MAPTRAB9AHTTHPGD
SCHEMBL2340180 0.76 FGFR1 (0.70) FGFR1MAPTRAB9AHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 US disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP FGFR1 2484/4885MAPT 368/4885RAB9A 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.